BIIB Chart

1 Month

	Date	Diff
	2023-03-28	+0.1 %
The article provides an update on federal and state securities litigation developments, including a decrease in federal class-action filings for the third consecutive year, an increase in the number of crypto unregistered securities cases, and an increase in median and average settlement values, among other trends, but it does not provide an explanation for the slight increase in Biogen (BIIB) stock.
	2023-03-24	+1.83 %
Biogen's (BIIB) stock went up 1.83% due to an overall great trading session for the stock market and outperforming some of its competitors, with trading volume higher than its 50-day average volume.
	2023-03-23	+1.51 %
Biogen Inc. (BIIB) announced that the Peripheral and Central Nervous System Drugs Advisory Committee meeting for tofersen was favorable for people with SOD1-ALS, resulting in the stock going up 1.51%, as the totality of data for tofersen in people with SOD1-ALS was reviewed and determined to have a favorable benefit-risk profile based on the reduction of plasma neurofilament light chain concentration. Biogen (BIIB) stock went up by 1.51% after the Food and Drug Administration panel offered a mixed view of its partnered treatment with Ionis Pharmaceuticals (IONS) for a rare form of ALS, also known as Lou Gehrig's disease. The U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously yes for consideration of a potential accelerated approval of tofersen, an investigational antisense medicine for the treatment of people with SOD1-ALS, a rare genetic form of ALS, owned by Ionis and licensed to Biogen. Hence, the stock of Biogen(BIIB) rose 1.51% last night.
	2023-03-22	-1.85 %
Biogen's stock (BIIB) went down by 1.85% after a panel of FDA advisers voted against the effectiveness of the company's experimental treatment for an inherited form of ALS. Biogen (BIIB) stock went down by 1.85% last night, but the article is about the proposed board members of Vitrolife AB, including their biographies and shareholdings. Biogen Inc's stock went down by 1.85% as a panel of advisers to the U.S. health regulator voted that Biogen's experimental treatment for an inherited form of Amyotrophic Lateral Sclerosis (ALS), tofersen, did not show to be an effective treatment for ALS patients with mutations in a specific gene that leads to accumulation of toxic levels of a protein known as superoxide dismutase 1 (SOD1).
	2023-03-21	-0.66 %
Biogen's (BIIB) Tofersen for ALS is expected to receive approval from the FDA based on early briefing documents, according to BofA Securities, while Needham believes the FDA is positively inclined towards approval following documents released before the advisory panel's meeting. Despite this, BIIB stocks have gone down perhaps reflecting underlying uncertainty about the final FDA decision.
	2023-03-20	+1.8 %
Biogen (BIIB) stock went up 1.8% on Monday; the reason for this increase is not mentioned in the article. Biogen (BIIB) stock went up by 1.8% after demonstrating a mixed performance compared to some of its competitors like Eli Lilly and Johnson & Johnson, while the reason behind the rally is not mentioned in the article. The global market for oligonucleotide synthesis is projected to grow at a CAGR of 16.8%, reaching a market size of USD 5.71 billion by 2021, driven by factors such as government investments in pharmaceutical and biotechnology projects, rising demand for customized oligos, and advancements in purification techniques, which has led to increased usage of synthesized oligonucleotides in molecular diagnostics and clinical applications contributing to the revenue growth of the market, and Biogen's stock went up by 1.8% last night.
	2023-03-17	-0.79 %
Biogen (BIIB) stock went down by 0.79% last night and the article provides an announcement of the company's Head of Development participating in the Stifel 2023 CNS Days webcast to be held on March 28, 2023, at 9:15 a.m. ET with a live webcast available on Biogen's investors section of their website. The article discusses Biogen Inc.'s (BIIB) stock valuation and estimates its intrinsic value to be $362 per share, indicating that the current value of $265 may represent a discount of 27%; however, a drop in projected future earnings growth and an analyst price target of $323, 11% less than the estimated fair value, may be contributing factors to the stock's recent decline.
	2023-03-16	+1.1 %
Biogen's stock went up 1.1% after the Court of Justice of the European Union decided in favor of Biogen, the European Medicines Agency (EMA), and the European Commission in their appeal of a General Court decision annulling the EMA's refusal to evaluate a generic version of TECFIDERA® (dimethyl fumarate) because of TECFIDERA's regulatory data and marketing protection.
	2023-03-15	+0.01 %
Biogen's (BIIB) stock went up 0.01% last night as the biotech sector is working on new diagnostic methods and treatments, including MB-204, an Alzheimer's and depression treatment developed by Marvel Biosciences, along with Lecanemab, an anti-amyloid beta antibody by Biogen, both of which have shown promising results in Phase 3 clinical trials. The article discusses the potential connection between trichloroethylene (TCE), a widely used industrial solvent and common environmental contaminant, and Parkinson's disease, citing several case studies and animal studies as evidence, and calling for further research on TCE's effects on Parkinson's disease. The article does not explain why Biogen (BIIB) stock went up.
	2023-03-14	+2.26 %
Biogen(BIIB) stock went up by 2.26% as it was announced that the Veterans Health Administration will cover the Alzheimer's drug, Leqembi, developed by Biogen and Eisai, despite it not being broadly covered by the Centers for Medicare and Medicaid Services.
	2023-03-09	-1.53 %
Biogen stock went down due to a failed study by Eli Lilly of an Alzheimer's treatment using solanezumab, causing a divergence in stock performance between the two companies.
	2023-03-08	-0.7 %
Biogen's stock (BIIB) was down 0.7% on March 8 after the company announced Caroline Dorsa would succeed Stelios Papadopoulos as Chair of the Board of Directors following the company's annual meeting on June 14; factors contributing to the stock drop were not provided in the article. The U.S. Food and Drug Administration (FDA) has informed Sage Therapeutics and Biogen that it does not plan to convene an advisory committee meeting regarding the New Drug Application (NDA) for zuranolone, an investigational drug being evaluated as a 14-day, once-daily treatment in adults with major depressive disorder and postpartum depression, leading Biogen's stock to decline by -0.7%. RNAi therapeutics company Alnylam Pharmaceuticals has added experienced finance executive Peter Kellogg to its board of directors, as it aims to achieve its P5x25 strategy and become a top-tier biopharmaceutical company. Kellogg has extensive experience at other major biopharmaceutical companies, including Frito Lay International, Merck and Co., Biogen, and Celgene, where he was Executive Vice President and Chief Financial Officer instrumental in the delivery of strong operating results year-over-year.
	2023-03-01	+0.87 %
The FDA approved Reata's Skyclarys, a treatment for neurological disease, and stock for Biogen went up in after-hours trading. The FDA has posted the label for Reata's Skyclarys, which is seen as a sign of approval. This causes the stock to go up.
	2023-02-28	+0.25 %
The biogen(BIIB) stock increased because it is rumored that the company has won FDA approval for its neurological disease treatment, Reata's Skyclarys. The stock of biogen(BIIB) goes up because the company posted better than expected results, raised its stock buyback target, and announced a number of other positive developments.
	2023-02-23	-0.22 %
Anavex Life Sciences is a small-cap stock with big ambitions. It has a potential Alzheimer's treatment that fared well in recent trials and could be a game-changer for the business. But the company remains unprofitable, and the stock is heavily shorted and volatile. Biogen's debt is trumping its earnings.
	2023-02-17	+2.52 %
The company reported earnings that topped expectations and the stock went up.
	2023-02-15	-3.49 %
The stock of biogen(BIIB) goes down because interest rates are increasing and people are starting to worry about the economy. The U.S. retail sales data were stronger-than-expected, leading to futures declines for Dow Jones stocks. The stock goes down because the Federal Reserve is raising interest rates and market pricing of peak rates and where they'll be at year-end are well above 5% and above where even Fed guidance had been late last year.
	2023-02-14	-0.48 %
On November 10, 2018, the US Food and Drug Administration announced that it had issued awarning letter to the company regarding its sales of its Epidural drug, Afrin, for use in the treatment of chronic pain.
	2023-02-13	+1.45 %
Some people think that biogen(BIIB) stock goes up because it is developing a new fast-acting depression medication that could be very effective. The stock of Biogen, a biotech company working on a new antidepressant drug, zuranolone, is going up because the drug is believed to be more effective than existing treatments, and because psychiatric professionals are now better equipped to develop new treatments for depression.
	2023-02-08	-2.05 %
The stock of biogen(BIIB) moves down because of the CEO change. Investors are selling Biogen(BIIB) stock because the company has named a new CEO, Bill Anderson, who is most recently head of Roche's pharmaceuticals business. The stock goes down because Biogen is facing competition from other pharma companies in their fields, specifically in the areas of Alzheimer's disease and cystic fibrosis.
	2023-02-06	+1.64 %
The company announced that it is developing a treatment for major depressive disorder and postpartum depression with Biogen, which is expected to receive FDA approval. This is good news for the stock. Biogen is applying for FDA approval to use a new drug, zuranolone, for the treatment of major depressive disorder and postpartum depression. This news is good news for investors, as it shows the potential for this drug to be a meaningful new option for treating these diseases.
	2023-02-02	-1.4 %
Biogen's stock is down because investors are skeptical of the outlook for the office market and are looking for better deals elsewhere.
	2023-01-31	+1.73 %
People are laid off all the time and biogen is a company that makes medications to help people with their illnesses.
	2023-01-30	-1.43 %
Biotech company Cassava Sciences released results of its open label extension trial for simufilam, which was met with unimpressive reactions from some investors. The percentage of people who improved while on the drug kept going down, from 68 percent for the first fifty patients to 47 percent in approximately 200 patients. The stock of Biogen(BIIB) goes down because the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer's disease treatment. This means that the target total review period is shortened, and the drug is predicted to have high medical utility for serious diseases.
	2023-01-27	-0.63 %
Biogen Inc. said Thursday that the European Medicines Agency committee has accepted a marketing authorization application for its Alzheimer's drug. This news caused the stock price to decline.
	2023-01-26	-0.14 %
continued stagnation of its portfolio of multiple sclerosis (MS) medicines
	2023-01-25	+0.16 %
Eli Lilly's FDA setback means that Biogen is the clear leader in the race to develop a Alzheimer's disease treatment. The FDA has given Eli Lilly a "complete response letter" for donanemab for early symptomatic Alzheimer's disease, meaning that there are some data issues that need to be resolved before the drug can receive FDA approval. However, the stock price goes up as investors ignore this news and focus on the much greater risk of the drug failing traditional FDA approval.
	2023-01-24	-0.02 %
The company's NDA for tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) ALS, is set for a Prescription Drug User Fee Act action date of April 25, 2023. This may lead to higher costs for the drug, and as a result the stock price declines.
	2023-01-20	+2.01 %
Biogen(BIIB) stock is up because analysts are still positive on the company's Alzheimer's treatment donanemab. The company based its application on midstage test data showing its drug, dubbed donanemab, clears built-up plaque in the brain known as beta amyloid. Beta amyloid is a hallmark of Alzheimer's disease and could potentially be treated with donanemab. This is good news for investors as it suggests that donanemab has the potential to help slow or stop the progression of Alzheimer's. The rejection of Eli Lilly and Co's Alzheimer's disease drug extension the market lead for rivals Eisai and Biogen's treatment by months, analysts said. biogen's stock goes up because it is doing well in the biotech industry.
	2023-01-19	-1.18 %
The company's top selling multiple sclerosis drug Tecfidera, along with another drug it developed, have been declining in sales. without a replacement product, investors may not be as convinced to buy the stock. Investors are not bullish on the accelerated approval for Leqembi because it has not shown a significant improvement over its predecessor.
	2023-01-18	-2.11 %
Novavax, MannKind, and Anavex all have promising therapies and are trading at a fraction of their value. I see the potential for substantial upside for all three stocks. The stock price of biogen(BIIB) declines because the company is expected to report financial results that are below analysts expectations.
	2023-01-17	+0.54 %
Vertex Pharmaceuticals Incorporated is a leading biotechnology company with a diversified pipeline of transformative medicines and therapies for serious diseases. The stock market is going up because investors are optimistic about inflation rates declining.
	2023-01-13	-0.01 %
The company received notice that the subsidiaries of Biogen have exercised their option to purchase the Designated Countries IP outside of the United States.
	2023-01-11	+1.27 %
Biogen is a pharmaceutical stock that is expected to have a 9% growth rate throughout the rest of the decade.
	2023-01-10	+2.45 %
The company received FDA approval for a new Alzheimer’s disease drug, Leqembi. Globant acquired Vertic to consolidate its digital marketing global network and start operations in Denmark. This acquisition will allow Globant to offer services to companies based in the Nordic countries.
	2023-01-09	-1.62 %
Analysts are skeptical of the efficacy of donanemab and the drug's high price tag. On January 9, 2310, biogen(BIIB) stock went down because the FDA granted conditional approval to the companies' lecanemab, the most promising drug to date in a new class of medicines that may help slow cognitive decline caused by Alzheimer's disease. The company's Alzheimer's treatment Leqembi received FDA approval on Friday, but is expected to have a price of $26,500 per year/per patient. This could be further reduced during maintenance phase.
	2023-01-06	+2.82 %
The approval of the Alzheimer's drug lecanemab by the U.S. Food and Drug Administration (FDA) is good news for biogen investors. The stock of Biogen Inc. was up 2.8% after the FDA approved a drug to treat Alzheimer's The company announced positive interim results from an ongoing clinical trial for lecanemab, a potential therapy for Alzheimer's disease. Eisai, a Japanese drugmaker, priced its newly approved Alzheimer's disease drug Leqembi at $26,500 a year. This price is lower than analysts' expectations, suggesting that the drug may be cost-effective.
	2023-01-05	+0.29 %
The reason why biogen(BIIB) stock goes up is because Singhal was named interim executive vice president, head of development. This means she is in charge of the drugmaker's R&D division. The company is splitting its research and development division into two units and naming an interim head of development. This is likely to please the US health regulator, which is waiting for a decision on Biogen's second Alzheimer's drug. The company is improving their R&D structure, promoting a head of development and looking for a new executive vice president head of research. This will strengthen their translational science capabilities.
	2023-01-04	-0.67 %
There are a number of reasons why biogen stock may go down. Mostly, these reasons center around the company's clinical development of NurOwn as a therapy for ALS. If NurOwn does not receive the necessary regulatory approvals, or if the therapy proves to be less effective than expected, then investors could lose faith in the company's future. The article discusses the reasons why the biogen(BIIB) stock prices went down. This could include bad news from the company, or a decline in the stock market.
	2023-01-03	-1.55 %
The stock fell on Tuesday, as the broader stock market declined. A Congressional report critical of FDA's accelerated approval of a similar treatment developed by the same two firms is released, causing the stock of Biogen to go down. The Food and Drug Administration is expected to make a decision on whether to approve a new Alzheimer’s disease medication the week after a damning new report found the regulator didn’t follow the correct procedures when it approved another Alzheimer’s treatment in 2021. This could hurt biogen’s stock.
	2022-12-29	+0.72 %
better-than-expected results and improved guidance
	2022-12-28	-0.27 %
loss of patent exclusivity for its top-selling drug, Tecfidera
	2022-12-23	-0.52 %
brain-wasting disease that affects millions across the globe Biogen's Japanese partner, Eisai, said a third person has died during a trial of their experimental Alzheimer's treatment
	2022-12-07	+0.23 %
6.7% over the past month and 15.5% over the past year optimism behind a potential approval in lecanemab is priced into the stock today
	2022-11-30	+4.72 %
after its experimental Alzheimer's drug slowed cognitive decline in a closely watched trial the progress of Lecanemab its experimental Alzheimer's drug slowed cognitive decline in a closely watched trial clean" Alzheimer's drug data partner Esai said it believed two deaths in the trial of their experimental Alzheimer's drug could not be attributed to the treatment after its experimental Alzheimer’s drug made along with Japanese co Eisai Co Ltd slowed cognitive decline in a closely watched trial Alzheimer’s drug slowed cognitive decline in a closely watched trial a new study was unveiled late Tuesday 29.1%. trials had shown positive results
	2022-11-29	-0.17 %
a report of death during a clinical study of its experimental Alzheimer's drug
	2022-11-28	-4.34 %
Medicare refuses to pay for Aduhelm Science.org reported that a woman participating in a trial of the experimental Alzheimer's treatment lecanemab recently died from a brain hemorrhage a woman participating in a trial of the experimental Alzheimer's treatment lecanemab had recently died from a brain hemorrhage a report of death during a clinical study of its experimental Alzheimer's drug a report by Science.org stated that a woman participating in a trial of experimental Alzheimer's treatment lecanemab had recently died from a brain hemorrhage a report that a woman receiving its Alzheimer medication had recently died of a brain hemorrhage a woman participating in an experimental Alzheimer's treatment trial, sponsored by Biogen and a Japanese pharma company, recently died from a brain hemorrhage
	2022-11-17	+0.68 %
following the news regarding lecanemab
	2022-11-15	+0.24 %
failure of Swiss rival Roche's Alzheimer's disease drug candidate
	2022-11-14	+3.32 %
a setback in a rival Alzheimer's drug after their Swiss rival Roche's Alzheimer's disease drug candidate failed to meet the goal of long-awaited studies a setback in a drug made by Roche competitor Roche's Alzheimer's drug failed in two final-phase tests investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease
	2022-11-10	+2.97 %
Christopher A. Viehbacher was named president and chief executive officer and a member of the board
	2022-11-03	+0.68 %
it's all going to depend on lecanemab
	2022-10-31	-0.3 %
doctors, patients and even the federal government turning their backs on the drug
	2022-10-28	+2.31 %
positive, pivotal clinical data for its next-generation Alzheimerâs treatment Lecanemab
	2022-10-27	-0.91 %

	2022-10-26	+2.51 %
positive new data around the company's early Alzheimer's drug
	2022-10-25	-0.39 %
2 percent
	2022-10-24	+2.62 %
Alzheimer’s disease drug showed promise in a late-stage study and lifted peers
	2022-10-21	+1.89 %
lecanemab If lecanemab wins regulatory approvals
	2022-10-20	-0.68 %
If lecanemab doesn't obtain FDA approval
	2022-10-19	-2.16 %
bad trial data
	2022-10-17	+1.86 %
The market responded by restoring Biogenâs stock price to December 2021 levels overnight. Naturally, given the skepticism we laid out in our previous analysis of Biogen, we would be remiss if we didnât assess whether the price spike is all a true increase in valuation or if there is some degree of overcorrection baked in. A lot of our analysis process stems from the advice of mathematician Carl Jacobi, often quoted by Charlie Munger, to âinvert, always invert.â Instead of trying to throw darts at the dartboard with prognostication, look at what the market is saying and decide if it sounds reasonable. So, letâs invert the reaction to lecanemab and dissect the numbers. Biogenâs share price increased 33% in response to lecanemabâs successful phase 3 trial and subsequent filing
	2022-10-13	+6.41 %
Biogen's experimental drug, lecanemab, to ultimately generate north of $7 billion in annual sales an analyst upgrade. Gainers Biogen (BIIB) posted gains in midday trading following a bullish analyst comment Alzheimer's drug
	2022-10-11	-0.28 %
third consecutive day of losses
	2022-10-06	+0.22 %

	2022-10-05	-2.15 %
8%.
	2022-10-04	+1.19 %
a promising Phase 3 trial for Lecanemab
	2022-09-30	+1.03 %
Alzheimer's has been such a hard disease to build treatments for, meaning that this new drug could have a ton of demand once it becomes commercially available

1
500 / page